CDKN2A and metastatic neoplasm: Alterations in BAP1 (20.6 vs. 14.1%; p = 0.036), CDKN2A (17.3 vs. 10.4%; p = 0.009), and FGFR2 (18.1 vs. 9.9%, p = 0.002) genes were more frequent among patients with primary versus metastatic iCCA, whereas alterations in SMAD4 (3.0 vs. 6.8%; p = 0.013) were more prevalent among patients with metastatic tumors (Table S1).